Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

l.

The pivotal study is expected to commence in the first quarter of 2009, with a potential projected BLA filing in late 2010. BioVex is currently commissioning its GMP manufacturing facility in Woburn, Massachusetts, which is intended to provide product for Phase III studies and launch.

Dr Robert Coffin, Chief Technology Officer for BioVex, said:

"This agreement with the FDA for the pivotal Phase III study design for OncoVEX(GM-CSF) in melanoma, which uses a very similar design as successfully employed in Phase II, is a significant event for BioVex. We believe the Phase II study results relating to durable objective response provide a sound basis on which to proceed with confidence to Phase III where the primary objective is to demonstrate a statistically significant increase in durable objective responses as compared to control therapy. We look forward to the presentation of the Phase II results at ASCO, and thereafter to the initiation of the pivotal study."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX(GM-CSF), is an unpartnered, first-in-class oncolytic, or cancer destroying virus technology. OncoVEX(GM-CSF) works by: 1) replicating and spreading within solid tumors, causing the death of cancer cells; while 2) stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. Based on the strength of the clinical data generated to date, coupled with a benign side effect profile, BioVex believes OncoVEX(GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors.

OncoVEX(GM-CSF) is currently complet
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in ... cancer, today announced that James A. Joyce , ... corporate overview at the 27th Annual ROTH Conference on ... was previously scheduled to present at 5:30 pm Pacific ... held at The Ritz-Carlton Hotel in Laguna ...
(Date:3/6/2015)... March 6, 2015  AbbVie (NYSE: ABBV ... Conference on Thursday, March 12, 2015. Richard A. ... in a question and answer session at 8:30 a.m. ... the presentation will be accessible through AbbVie,s Investor Relations ... of the session will be available later that day. ...
(Date:3/6/2015)... WOONSOCKET, R.I. , March 6, 2015 ... Chief Medical Officer of CVS Health (NYSE: ... on Health in Washington, D.C. ... a critical role in addressing health care cost and ... stress.  After making CVS/pharmacy the first national pharmacy chain ...
Breaking Medicine Technology:Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3
(Date:3/6/2015)... March 06, 2015 Follow us ... the pharmacokinetics of a drug refers to testing of ... inside an organism. When toxicity studies are clubbed together ... or ADME/Tox. Increasing focus on lowering costs and time ... testing worldwide. The traditional drug development model uses toxicity ...
(Date:3/6/2015)... 06, 2015 Parents need to start ... of substance use disorders. School programs like DARE, or ... successful. NOPE, or Narcotics Overdose Prevention and Education has ... Healthline News on Feb. 27th. As teens ... opiate drugs, drug prevention proponents are lobbying Florida to ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
(Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
(Date:3/6/2015)... The Gluten-Free Certification Program (GFCP), ... pleased to announce that Dufflet Pastries, the ground-breaking ... their product line of gluten-free treats certified by ... as satisfying as any of their other desserts! ... contains hydrogenated fats or oils, artificial flavours, colours ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... Technologies, makers,of a gamma imaging system optimized for ... with Amerinet, a leading national,group purchasing organization. Effective ... healthcare providers and their,patients, access to the Dilon ... early stage breast cancers., "Dilon Technologies is ...
... Dynamics Company,Ltd.) (TSX: IDL), the global leader in ... announced the appointment of Mr. Rodolfo,Gutierrez as Vice ... a veteran of the imaging industry, will be ... development, distribution,service and product sales in the region., ...
... Philadelphia, PA, July 16, 2008 Anxiety is a ... can develop into a disabling disorder of excessive and ... posttraumatic stress disorder. Effective treatments are available and ... "it makes intuitive sense that combining these two treatments ...
... are taking adequate steps to address the cost of ... York, California and North Carolina are facing tens ... myths and realities of this potential crisis are laid ... Robert Clark, a professor of economics and of management, ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) announced today that ... is anticipated to begin,shortly through Renewed Hope Clinic ... exclusive license agreement for the,administration and distribution of ... Laboratories, LLC., Immunosyn has been advised by ...
... cross contaminations including Norovirus ... ... Shield LLC has begun,shipping a new family of fully submersible, 108 ... risk,of worldwide cross contaminations, including Norovirus and the "superbug,",MRSA. According to ...
Cached Medicine News:Health News:Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging 2Health News:IDC appoints new Vice President for Latin America 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah 2Health News:Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah 3Health News:Seal Shield to Launch World's First Dishwasher Safe, Antimicrobial Keyboard with Multi-Language Support for International Markets 2
Denman brown nucleus cracker with 30 angled shafts, tip to angle length 14.5 mm. Standard cross action handle. 1.1 mm x 1.2 mm paddle style tips....
Nucleus cracker....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, delicate, straight....
Medicine Products: